Cutaneous Toxicities of Cancer Therapy

Wednesday, July 15, 2026, 12:00 PM - 1:00 PM, SHC South Bay Cancer Center, 2589 Samaritan Dr, San Jose, CA 95124 (Room 3300A)

This 1-hour course is designed for the Registered Nurse or Advanced Practice Provider who is interested in a more comprehensive understanding of cutaneous toxicity related to cancer therapy. Topics in this session include cutaneous side effects and dermatologic treatment options. By the end of the course, learners will increase their knowledge about dermatologic treatment modalities.

1. Identify common cutaneous side effects of chemotherapy and targeted cancer therapies.
2. Provide examples of initial treatment recommendations for cutaneous toxicities caused by chemotherapy or biotherapies.
3. Recognize when referral to specialist (cutaneous oncology and supportive dermatology) is indicated
4. Recognize own implicit bias related to personal appearance and use open-ended questions to explore patient priorities

ANCC - American Nurses Credentialing Center contact hour(s) (1.00 hours), CA BRN - California Board of Registered Nurses contact hour(s) (1.00 hours), General Attendance (1.00 hours)

1. Stanford Health Care is a provider approved by the California Board of Registered Nursing (BRN).  Provider Number CEP12165.
2. Stanford Health Care is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. 

 

©2026 by Stanford Health Care, Division of Patient Care Services.
All rights reserved. No audio or video taping allowed. We reserve the right to make program changes. All students must be registered, attend the entire course, and submit an evaluation after course completion to earn credit hours.

 

Mitigation of Relevant Financial Relationships

Stanford Health Care (SHC) adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.